SignatureFD’s Neumora Therapeutics NMRA Stock Holding History

SignatureFD’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-264	Closed	-$515	–	3588
2026 Q1	$515	Buy	+264	New	+$684	﹤0.01%	3306

Other funds holding NMRA

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SignatureFD's NMRA Position: Q2 2026 in Review

SignatureFD sold out of Neumora Therapeutics (NMRA) in Q2 2026, closing a stake of 264 shares — an estimated $515 sold.

SignatureFD first reported a position in NMRA in Q1 2026 and held it in 1 quarter. The position peaked at $515 in Q1 2026. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

SignatureFD reported no remaining Neumora Therapeutics position as of Q2 2026 after selling out during the quarter.
SignatureFD sold 264 Neumora Therapeutics shares in Q2 2026, an estimated $515.
SignatureFD first reported a position in Neumora Therapeutics in Q1 2026 and held it in 1 quarter.
SignatureFD's Neumora Therapeutics position peaked at $515 in Q1 2026.
113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.